Brief: Ultragenyx Gets Breakthrough Therapy Tag for GTX-102 in Angelman Syndrome Treatment
27/06/2025 13:03
June 27 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O: ULTRAGENYX RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR GTX-102 IN ANGELMAN SYNDROME ULTRAGENYX PHARMACEUTICAL INC - RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR GTX-102 Source text: ID:nGNXcd0FLB Further company coverage: RARE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx